Insys Therapeutics Inc
Why Insys Therapeutics Fell More than 70% Yesterday
Insys Therapeutics (INSY) released its first-quarter earnings results on May 10.
How INSYS Therapeutics’ Earnings Were Trending
In the first nine months of 2018, INSYS Therapeutics’ (INSY) net income and diluted EPS amounted to $78.1 million and $1.06, respectively.
How Is INSYS Therapeutics Financially Positioned in January?
In the first nine months of 2018, INSYS Therapeutics’ net revenues declined ~40% YoY to reach $109.2 million from $65.7 million.
Cannabis Stock INSYS Therapeutics Has Risen 28% in January
On January 10, INSYS Therapeutics stock closed at $4.49, which represents ~28% growth from its stock price of $3.50 at the close of markets on December 31.
A Look into GW Pharmaceuticals’ Revenue Trends
In the fourth quarter of fiscal 2018, GW Pharmaceuticals (GWPH) generated revenues of $2.42 million compared to $2.45 million in the same period the prior year.
Analyzing 22nd Century Group’s Year-to-Date Performance
Analysts expect 22nd Century Group to report revenue of $23.3 million in 2018, a 40.3% rise compared to $16.6 million in 2017.
A Closer Look at Insys Therapeutics’ Performance Year-to-Date
Insys Therapeutics (INSY) is among the specialty pharmaceutical companies that focus on developing cannabinoids and sprays.
How Marijuana-Focused Biotech Companies Have Performed in 2018
In this series, we’ll discuss analysts’ estimates, recommendations, and revenue estimates for marijuana biotechnology companies.
Marijuana-Focused Biotech Companies in Q3: Are They Performing?
In this series, we’ll look at biotechnology companies focused on marijuana-based products and how they performed in the third quarter.
Vermont Legalizes Recreational Marijuana on January 22, 2018
On January 22, Vermont decriminalized the possession of marijuana for adults 21 and older. Vermont became the ninth state to legalize marijuana for recreational purposes.
The Other Side of Legalizing Recreational Marijuana
While marijuana legalization for recreational use is just gaining attention around the world, it’s also facing strong opposition. According to some, legalizing marijuana will just increase substance abuse.
The Marijuana Ecosystem’s Potential Business Opportunities
Given that legislative approval is the strongest driving factor behind the boost in the marijuana industry, companies have rushed to capitalize on the wave.
Is Investment in the Marijuana Space Picking Up?
In the previous part of this series, we saw that the alcohol industry could expect marijuana legalization for recreational purposes as an extension to their growth strategy.
How Marijuana Acceptance Is Evolving Globally
It’s fascinating to see how the marijuana landscape around the world has evolved in the last three years. According to Canopy Growth (WEED.TO), Canada, Israel, the Czech Republic, Uruguay, and the Netherlands “established federally legal cannabis access regimes” in 2014.
Must-Knows before Investing in the Marijuana Industry
In our recent series Should You Jump on the Marijuana Bandwagon? we briefly touched upon the marijuana industry from an investment perspective.
What Are Insys Therapeutics’ Top Priorities?
Insys has brought new leadership on board with the appointment of Saeed Mohatari as the company’s new CEO and Andrew Long as the new CFO.
Insys Has Legal Issues Galore
In December 2016, the U.S. Attorney’s office for the District of Massachusetts issued an indictment against six former Insys (INSY) employees.
What’s behind Insys Therapeutics’ Legal Tangles?
Insys received a subpoena in December 2013 from the inspector general of HHS for an investigation of potential violations that involved HHS programs.
Gauging Marijuana Risk: The Potential Investment Blowback
Investing in the marijuana industry—at least in its current stage in the US—certainly comes with its own set of risks.
What Analysts Recommend for Insys Therapeutics and Peers
Insys Therapeutics (INSY) is a commercial-stage specialty pharmaceutical company headquartered in Chandler, Arizona.
The SPDR S&P Biotech ETF Lingers in the Red as of December 3
The SPDR S&P Biotech ETF (XBI) went down by 3.9% on December 3, which represents the third consecutive day of declines for the ETF. XBI closed at $68.91.